Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Introduction (0:00)
• Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32)
• Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59)
• Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53)
• Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41)
• Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39)
• Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44)
• Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16)
• Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14)
• Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19)
• Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04)
• Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07)

CE information and select publications